This Week in Gastroenterology — May 14, 2026

Welcome to This Week in Gastroenterology. This week we're covering 10 notable papers spanning new insights in steatotic and alcohol-related liver disease, evolving strategies for managing viral hepatitis D, and advances in diagnostics and therapeutics for chronic liver disease and IBD. Let's dive in.

The Spectrum of Steatotic and Alcohol-Related Liver Disease

We begin with the vast and evolving field of steatotic liver disease, or SLD. A large analysis from the UK Biobank, published in Alimentary Pharmacology & Therapeutics, sought to define the natural history of different SLD subtypes [7]. Researchers evaluated nearly 245,000 participants, categorizing them into metabolic dysfunction-associated SLD, or MASLD; metabolic dysfunction and alcohol-associated liver disease, or MetALD; and alcohol-associated liver disease, or ALD. Over a median follow-up of 13.5 years, the findings confirmed that ALD carries the highest risk for major adverse liver outcomes, major adverse cardiovascular events, and all-cause mortality. However, the study also revealed a crucial distinction: patients with MetALD had a higher risk of major liver outcomes compared to those with MASLD alone, although their cardiovascular and mortality risks were similar. This highlights that any amount of significant alcohol use in the setting of metabolic dysfunction amplifies the risk of liver progression.

Building on this, a study in Clinical Gastroenterology and Hepatology provides more granular data on fibrosis progression rates in patients with MetALD and ALD [1]. Using paired liver biopsies taken about two years apart, investigators found an overall fibrosis progression rate of 0.22 stages per year. The critical clinical message was the impact of ongoing alcohol consumption. Patients with active alcohol use at baseline had a more than two-fold increase in their progression rate, advancing one fibrosis stage every three years, compared to every eight years for those who were abstinent. This study also provides a crucial insight for future clinical trials. It showed that changes in non-invasive biomarkers like LiverPRO, PRO-C3, and FIB-4 predicted adverse outcomes just as well as changes in histological fibrosis stage. This supports their use as surrogate endpoints, which could accelerate drug development in this space.

While lifestyle changes are paramount, we also have new evidence for pharmacological intervention. A study in The American Journal of Gastroenterology investigated the real-world impact of GLP-1 receptor agonists on liver outcomes [10]. Using data from the All of Us Research Program in the United States, researchers conducted a retrospective cohort study of over 4,000 individuals with both MASLD and type 2 diabetes. They found that patients using GLP-1 receptor agonists had a significantly lower risk of major hepatic complications, which included cirrhosis, decompensation, hepatocellular carcinoma, or liver transplant. The intention-to-treat analysis showed a 38% relative risk reduction over a median follow-up of 2.7 years. This real-world evidence strongly supports a hepatoprotective effect for GLP-1 agonists in this high-risk population.

Finally, in a mechanistic study with significant clinical implications, research in the Journal of Hepatology explored how rifaximin might ameliorate portal hypertension [8]. The preclinical study, validated in a human cohort, found that the gut microbiome-derived secondary bile acid, deoxycholic acid or DCA, was positively correlated with portal pressure. Rifaximin, a non-absorbable antibiotic, was shown to reduce portal pressure by decreasing these DCA levels. The mechanism involves DCA increasing serum serotonin, which in turn triggers portal vein smooth muscle contraction. By reducing DCA, rifaximin interrupts this pathway. This provides a novel, microbiome-targeted mechanism of action for rifaximin in managing a key driver of cirrhosis-related complications.

New Perspectives on Hepatitis D Virus

Next, we turn to two papers that provide a fuller picture of the natural history and outcomes of chronic hepatitis D, or HDV.

A study in Hepatology from a large Mongolian cohort examined the predictors of spontaneous HDV suppression in over 1,600 treatment-naive patients [9]. Over a median follow-up of nearly four years, about 8% of patients achieved spontaneous suppression by year five. The key finding was the identification of predictors. Diabetes and male sex were associated with a higher likelihood of suppression. Conversely, higher baseline levels of HBsAg, HDV RNA, and ALT were all associated with a lower chance of suppression. These factors can help clinicians risk-stratify patients and inform decisions about when to initiate emerging anti-HDV therapies.

For patients whose disease progresses to end-stage, a second study in Clinical Gastroenterology and Hepatology provides important insights into liver transplantation outcomes [5]. Analyzing twenty years of data from both European and United States registries, researchers compared over 2,300 HBV/HDV co-infected transplant recipients to over 10,000 HBV mono-infected recipients. The data show that HDV patients were transplanted at a younger age and with more advanced liver disease, reflected by higher MELD scores and more ascites. Despite this worse pre-transplant profile, the HDV group had significantly better post-transplant survival at 1, 5, and 10 years. This underscores both the aggressive nature of HDV leading to transplant and the favorable outcomes that can be achieved once transplantation occurs.

Refining Risk Stratification in Chronic Liver Disease

This week also brings two papers focused on improving how we diagnose and prognosticate specific chronic liver diseases.

First, for primary sclerosing cholangitis, or PSC, a multicenter study in Clinical Gastroenterology and Hepatology introduces a new prognostic tool called the HelPSCore [6]. Recognizing the highly variable course of PSC, the researchers developed and validated this time-dependent score to predict a composite endpoint of hepatobiliary malignancy, liver transplantation, or liver-related death. The HelPSCore demonstrated robust predictive accuracy over 25 years and significantly outperformed existing models like the Mayo model, MELD score, and UK-PSC risk score. With an AUC of 0.82 in the validation cohort, this simple tool could help identify high-risk patients who need more intensive monitoring and may be candidates for future therapies.

Second, an international Delphi consensus published in Hepatology provides much-needed clarity on the entity previously known as PBC-AIH overlap syndrome [3]. Seventy-four hepatologists and 14 liver pathologists reached a consensus on several key points. They agreed that the condition should be defined as a PBC-AIH 'variant' rather than an 'overlap syndrome'. A liver biopsy is now considered a prerequisite for diagnosis. The panel also agreed that the diagnosis should be periodically re-evaluated, as features can appear sequentially over time. Crucially, they noted that the PBC-AIH variant is associated with a worse prognosis than PBC alone unless it is treated with immunosuppression, the choice of which should be guided by the severity of interface hepatitis.

Confronting Therapeutic Challenges

Our final section addresses two major challenges in modern gastroenterology: antimicrobial resistance and the perceived limits of IBD therapy.

From India, a multicenter study in Alimentary Pharmacology & Therapeutics sounds the alarm on antimicrobial resistance in spontaneous bacterial peritonitis [4]. Among 319 patients with culture-positive ascitic fluid infections, multi-drug resistant organisms, or MDROs, were found in over half of cases, and carbapenem-resistant organisms, or CROs, were found in nearly a quarter. Independent predictors for MDRO infection included nosocomial acquisition, circulatory failure, high leukocyte count, and prior SBP prophylaxis. Worryingly, MDRO infection was associated with poorer survival. Another critical finding was that patients with non-neutrocytic bacterascites—that is, a positive ascitic fluid culture but a neutrophil count below 250—had similar mortality to those with classic SBP. The authors propose an empiric treatment framework based on clinical setting and risk factors, urging a move away from a one-size-fits-all approach.

Finally, a Viewpoint in The Lancet Gastroenterology & Hepatology challenges the widely held notion of a 'therapeutic ceiling' in inflammatory bowel disease [2]. The authors argue that the 30-50% remission rates seen with single-agent biologics are not a biological limit, but rather a consequence of our current methods: late intervention, reliance on monotherapy, and restrictive clinical trial designs. They outline a strategic framework to break this ceiling through prevention, early disease interception, and innovation in trial methodology, such as adaptive and platform trials. The piece is a call to action to shift from empiricism to a mechanism-based, precision medicine approach, integrating combination therapies and novel cell-based interventions to redefine remission in IBD.

Editor's Pick

If you only have time for one paper this week, make it the study on GLP-1 receptor agonists and liver outcomes from The American Journal of Gastroenterology [10]. In a large, diverse, real-world cohort of patients with MASLD and type 2 diabetes, GLP-1 RA use was associated with a nearly 40% reduction in major hepatic complications. This provides the strongest evidence to date that this class of drugs can bend the natural history curve for a disease affecting millions of patients.

Clinical Bottom Line

Here are the key takeaways from this week in Gastroenterology.

First, in patients with steatotic liver disease, alcohol-associated liver disease carries the highest risk, but even the combination of metabolic risk factors and alcohol—MetALD—confers a higher risk of liver events than MASLD alone [7, 1].

Second, for your patients with MASLD and type 2 diabetes, real-world data now support the use of GLP-1 receptor agonists to reduce the risk of major hepatic complications, including cirrhosis and decompensation [10].

Third, in patients with cirrhosis and ascites, be aware that over half of SBP isolates may be multi-drug resistant, especially in healthcare-associated cases. Consider a risk-stratified approach to empiric antibiotics, and remember that culture-positive non-neutrocytic bacterascites carries a similar mortality risk to classic SBP [4].

Fourth, for patients with PSC, a new tool called the HelPSCore shows superior long-term prognostication compared to older models like Mayo and MELD, potentially helping to identify high-risk individuals for closer monitoring [6].

And finally, an international consensus now defines PBC-AIH as a distinct 'variant,' not an 'overlap syndrome,' requiring a liver biopsy for diagnosis and mandating immunosuppression for significant interface hepatitis [3].

That's your roundup for This Week in Gastroenterology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.